Dr. Apoorva Jayarangaiah MARSHFIELD CLINIC- Saint Joseph s Hospital

Similar documents
Case Studies: Congenital Platelet Disorders

QUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)

V.N. KARAZIN KHARKOV NATIONAL UNIVERSITY

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College

Contemporary perspectives and initial management of pediatric ITP. William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA

Pharmacy Prior Authorization

Thrombocytopenia. Dr Lynda Vandertuin May 6, 2014

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data

ITP- Immune Thrombocytopenia : A Case Report

Pharmacy Prior Authorization

Cynthia Fata, MD, MSPH 6/23/15

Measuring Thrombopoietin

Acute Immune Thrombocytopenic Purpura (ITP) in Childhood

Hemostatic System - general information

GOOD MORNING! Thursday, July Heidi Murphy, MD Leslie Carter-King, MD

EDUCATIONAL COMMENTARY PLATELET DISORDERS

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

Miss. kamlah ahmed 1

Platelet Disorders. By : Saja Al-Oran

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

For platelet control as individual as you

Idiopathic Thrombocytopenic Purpura

HEME 10 Bleeding Disorders

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

Anemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017

BLEEDING (PLATELET) DISORDER. IAP UG Teaching slides

Thrombocytopenia: a practial approach

Mayo Clin Proc, November 2003, Vol 78 Sebastian Platelet Syndrome 1417 extremities and slight hyperextensibility of hand and wrist joints, suggesting

Diagnosis and Management of Immune Thrombocytopenias. Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016

Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN

Blood Components & Indications for Transfusion. Neda Kalhor

BLEEDING DISORDERS Simple complement:

eltrombopag (Promacta )

PROMACTA (eltrombopag olamine) oral tablet and oral suspension

INTRODUCTION TO SET FORTH APROACH TO MANAGING ADULTS TO SET FORTH APROACH PRIMARY ( PRIMARY AUTOIMMUNE) AUTOIMMUNE ITP FROM ASH & THE BRITISH

The Child with a Hematologic Alteration

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

Platelet disorders. Information for families. Great Ormond Street Hospital for Children NHS Foundation Trust

IMMATURE PLATELETS CLINICAL USE

Chronic Lymphocytic Leukemia (CLL)

Neutropenia Following Intravenous Immunoglobulin Therapy in Pediatric Patients with Idiopathic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13

Pathology note 8 BLEEDING DISORDER

Customer Information Literature List Platelets

Congenital bleeding disorders

Taking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss

Case Report Pseudothrombocytopenia due to Platelet Clumping: A Case Report and Brief Review of the Literature

DRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)

Dr Kannan S Consultant Hematologist Sahyadri Speciality Hospital, Pune K E M Hospital, Pune

There are two main causes of a low platelet count

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital

Bleeding disorders. Hemostatic failure: Inappropriate and excessive bleeding either spontaneous or in response to injury.

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable

Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89

Guidelines for Shared Care Centres and Community Staff

UKITP INITAL INFORMATION SHEET (2.4)

Case Report Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report

Chapter 06 Lecture Outline. See separate PowerPoint slides for all figures and tables preinserted into PowerPoint without notes.

Use of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia

Inherited thrombocytopenia: when a low platelet count does not mean ITP

* Renal insufficiencies

DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL

ASH Draft Recommendations for Immune Thrombocytopenia

What You Need to Know About Blood Transfusion. Elianna Saidenberg May 2014

Most Common Hemostasis Consults: Thrombocytopenia

Evaluation Of Bleeding Disorders /AAP Baton Rouge. Raj Warrier

THROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11

REVIEW ARTICLE. Immune Thrombocytopenic Purpura ADARSH A K, LAKSHMI KRISHNA INTRODUCTION CLASSIFICATION

Bleeding Disorders: (Hemorrhagic Diatheses) Tests used to evaluate different aspects of hemostasis are the following:

Interpreting the CBC. Robert Miller PA Assistant Professor of Clinical Pediatrics and Family Medicine USC Keck School of Medicine Retired

Cigna Drug and Biologic Coverage Policy

GLANZMANN S THROMBASTHENIA. Stacey Shiovitz January 13, 2012

Chapter 46. Care of the Patient with a Blood or Lymphatic Disorder

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D.

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Case Presentation. A Case from the Clinic. Additional Data. Examination and Data 10/27/2013

THE OLD AND THE NEW OF ITP. Alison Street Malaysia April 2010

Let`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016

Immune Thrombocytopenic Purpura (ITP)

r). SUPPLEMENTARY/SECOND OPPORTUNITY EXAMINATION PAPER nnmlbih UNIVERSITY Sophia Blaauw INSTRUCTIONS FACULTY OF HEALTH AND APPLIED SCIENCES

Expert Review: Updates in Immune Thrombocytopenia. Reference Slides

Easy Bleeding General Presentation

Bleeding Disorders HOPE Maram Al-anbar

Thrombocytopenia with Decreased Megakaryocytes

Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary

ACCME/Disclosures 4/13/2016. Clinical History

Anemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi

Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation with Eltrombopag

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Bleeding Disorders.2 MS Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD

Second line therapy for ITP should be TPO agonists. Nichola Cooper Imperial Health Care NHS Trust

Use of TPO mimetics for Indications Other Than ITP

Complement Blockade with C1 Esterase Inhibitor in Refractory Immune Thrombocytopenia

Schematic Of Heparin Induced Thrombocytopenia Platelet Count

Glomerular diseases mostly presenting with Nephritic syndrome

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable

The Oklahoma ITP Registry Newsletter July 2011

Scottish Medicines Consortium

Transcription:

Dr. Apoorva Jayarangaiah MARSHFIELD CLINIC- Saint Joseph s Hospital A 30 year old G1P0 female of Korean descent was referred by her OBGYN during her 2 nd trimester to the Hematology Clinic for evaluation of persistent thrombocytopenia of 11,000. ü ü Thrombocytopenia dates back prior to pregnancy Typically, patient s platelet counts ranged from 20,000 to 30,000 1

} At the age of 16 Menorrhagia & Petechiae Platelet count: 10,000 Other causes excluded; HIV, EBV, autoimmune drugs, FH Peripheral smear: Giant platelets Immune thrombocytopenic purpura Bone marrow Bx: increased number of megakaryocytes with normal morphology Coagulation panel: increased BT, normal PT, PTT Immune Thrombocytopenic Purpura } She was initiated on steroids and IV immunoglobulins. } She then underwent splenectomy, as there was no response to initial treatment. } Patient was also maintained on Rituximab for a short period with no improvement. 2

} Menorrhagia had been controlled with oral contraceptive pills } She had received weekly injections of Romiplastin to help decrease her bleeding risk. } She was supported by repeated platelet transfusions perioperatively and during symptomatic phases. 4 years after the diagnosis of ITP, the patient presented with renal failure, hematuria and proteinuria. She quickly progressed to End Stage Renal Disease (ESRD). o Around the same time, she also developed cataracts and progressive sensorineural hearing loss. 3

Nephritis Alport Syndrome Cataracts hearing loss Due to presence of syndromic features of sensorineural hearing loss, renal failure and cataracts diagnosis was presumed to be Alport s syndrome Alport syndrome o Patient underwent renal transplant- living related kidney donor (from half brother). o Currently maintained on Tacrolimus and Prednisone 5 mg. 4

} The patient is asymptomatic. } Vital signs are within normal limits. Physical examination is normal; No petechiae or ecchymoses noted. LABAROTORY WBC: 10.3 Hemoglobin: 14.0 Hematocrit: 43 Platelet count:11,000 5

Macrothrombocytopenia Refractory ITP Nephritis Alport Syndrome Cataracts hearing loss Nephritis Alport s Syndrome??? Cataracts hearing loss Macrothrombocytopenia 6

Genetic testing ü First discovered by Epstein in 1972 ü 4 overlapping syndromes of MYH-9 disorders: Epstein Syndrome, May-Hegglin, Sebastian, Fechtner Syndrome 7

Non muscle myosin heavy chain gene (NMMHC-IIA) ü Present in platelets as well kidneys, leukocytes, lens and cochlea ü Important cytoskeletal contractile protein in hematopoietic stem cells - Thrombocytopenia Immune Thrombocytopenic Purpura Epstein syndrome (MYH-9 related disorders) Alport s syndrome Genetics Acquired vs congenital AD; Congenital XD; Congenital Pathogenesis Platelet-glycoprotein specific auto abs Peripheral smear Bone marrow biopsy Giant platelets (~ 10%) Increased megakaryocytes w/ normal morphology MYH-9 gene- NMMHC-IIA mutation Giant platelets; MPV Neutrophilic inclusions bodycytoplasmic aggregates of NMMHC-IIA Increased megakaryocytes w/ normal morphology Low Platelets ü ü Type IV collagen Normal - - Other clinical findings None deafness, Cataracts, Nephritis deafness, Nephritis, Cataracts, Lenticonus 8

} Importance of differentiating between MYH-9 gene disorders and ITP } Early recognition of MYH-9 disorders can be beneficial in avoiding unnecessary procedures, referral to genetic counseling and preventative measures } Law of diagnostic parsimony or Occam s Razor } Althaus K, Greinacher A. MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis. Transfus Med Hemother, 2010 (5); 260-267 } Vassallo D, Erekosima I et al. Myosin heavy chain-9- related disorders (MYH9-RD); a case report. Clin Kidney J 2013 Oct(5); 516-518 } Ryhanen SJ, Antitila P. Hereditary macrothrombocytopenia and hearing loss. Duodecim 2015; 131(9); 871-874 } Kaushansky, K., & Williams, W. J. (2010). Williams hematology. New York: McGraw-Hill Medical. 9